<p>Cypress Capital Group 在第二季度減持了 Hologic, Inc.（NASDAQ:HOLX - Free Report）的持股，根據該公司最近向證券交易委員會（SEC）提交的文件，持股比例下降了 75.9%。該公司在此期間賣出了 9,607 股，持有這家醫療設備提供商的 3,050 股股票。截至最近一次提交的 SEC 文件，Cypress Capital Group 持有的 Hologic 股份價值 226,000 美元。</p>
<ul>
<li>是時候購買這 3 家提高收入預測的醫療公司了嗎？</li>
</ul>
<p>其他幾家對沖基金和機構投資者最近也買入和賣出了該公司的股票。iA Global Asset Management Inc.在第一季度新建了 Hologic 的頭寸，價值約 37,000 美元。Mather Group LLC.在第一季度購入了一份價值約 48,000 美元的 Hologic 股票。Massmutual Trust Co. FSB ADV 在第一季度將其在 Hologic 的持倉增加了 24.7%。Massmutual Trust Co. FSB ADV 現在擁有 691 股這家醫療設備提供商的股票，價值 54,000 美元，比上一季度增加了 137 股。Toth Financial Advisory Corp 在第一季度將其在 Hologic 的持股增加了 81.1%。Toth Financial Advisory Corp 現在擁有 775 股這家醫療設備提供商的股票，價值 60,000 美元，比上一季度增加了 347 股。最後，Fidelis Capital Partners LLC 在第一季度購入了一份價值約 63,000 美元的 Hologic 股票。94.73% 的股份由對沖基金和其他機構投資者持有。</p>
<h2>Hologic 股價表現</h2>
<p>NASDAQ HOLX 股票在週五的午間交易中上漲了 0.16 美元，達到 80.25 美元。公司股票交易量為 1,106,135 股，相比其平均交易量 1,648,404 股有所下降。Hologic, Inc.的 52 周最低價為 64.02 美元，52 周最高價為 84.67 美元。該公司的市值為 187.3 億美元，市盈率為 40.94，市盈增長比為 2.64，貝塔係數為 0.99。股票的 50 天簡單移動平均線為 77.75 美元，200 天簡單移動平均線為 76.14 美元。公司的資產負債比為 0.51，流動比率為 3.99，速動比率為 3.29。</p>
<ul>
<li>蝴蝶網絡能否在 2023 年擴展業務？</li>
</ul>
<p>Hologic（NASDAQ:HOLX - Get Free Report）於 7 月 29 日星期一公佈了其季度收益結果。這家醫療設備提供商報告稱，該季度每股收益為 1.06 美元，超過了 1.02 美元的共識預期 0.04 美元。該季度公司收入為 101 億美元，而分析師預計為 100 億美元。Hologic 的淨利潤率為 17.59%，淨資產回報率為 19.53%。公司季度收入同比增長了 2.7%。在去年同期的同一季度，該公司每股收益為 0.93 美元。股票研究分析師預計，Hologic, Inc.本財年的每股收益將達到 4.08 美元。</p>
<h2>Hologic 內部交易活動</h2>
<p>在其他 Hologic 新聞中，首席執行官 Stephen P. Macmillan 於 7 月 17 日星期三交易中出售了 3,672 股 Hologic 股票。這些股票的平均價格為 80.13 美元，總交易額為 294,237.36 美元。交易完成後，首席執行官現在擁有公司股票 1,157,562 股，價值約 92,755,443.06 美元。該交易已在提交給證券交易委員會的文件中披露，可在此鏈接找到。另外，首席執行官 Stephen P. Macmillan 於 7 月 17 日星期三的交易中出售了公司股票 3,672 股。股票的平均價格為 80.13 美元，總價值為 294,237.36 美元。交易完成後，首席執行官現在直接持有公司股票 1,157,562 股，價值約 92,755,443.06 美元。該交易已在證券交易委員會的法律文件中披露，可通過 SEC 網站訪問。此外，內部人員 Brandon Schnittker 於 8 月 6 日星期二的交易中出售了 476 股 Hologic 股票。這些股票的平均價格為 83.11 美元，總價值為 39,560.36 美元。交易完成後，該內部人員現在持有公司股票 3,735 股，價值 310,415.85 美元。過去三個月，內部人員已出售了價值 1,469,973 美元的 18,280 股公司股票。公司內部人員持有公司股份的比例為 1.75%。</p>
<h2>分析師評級變動</h2>
<p>一些研究公司最近發佈了關於 HOLX 的報告。加拿大皇家銀行重申了對 Hologic 的 “行業表現” 評級，並設定了 82.00 美元的股價目標。Needham \u0026 Company LLC 重申了對 Hologic 的 “買入” 評級，並設定了 90.00 美元的目標股價。StockNews.com 將 Hologic 的股票評級從 “強買” 調降至 “買入”，並在 8 月 10 日的報告中指出。Stephens 重申了對 Hologic 的 “增持” 評級，並設定了 92.00 美元的股價目標。最後，Argus 將 Hologic 的目標股價從 89.00 美元上調至 95.00 美元，並給予該公司 “買入” 評級。四家研究分析公司對該股票給予持有評級，八家給予買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “中度買入”，平均目標股價為 87.60 美元。</p>
<p><strong>獲取我們對 HOLX 的最新股票分析</strong></p>
<h2>Hologic 簡介（免費報告）</h2>
<p>Hologic, Inc（豪洛捷公司）開發、製造和供應診斷產品、醫學影像系統和婦女健康手術產品，通過早期檢測和治療服務於婦女健康。該公司通過四個部門運營：診斷、乳腺健康、婦科手術和骨骼健康。它提供 Aptima 分子診斷試劑以檢測感染微生物；Aptima 病毒載量試劑用於乙型肝炎病毒、丙型肝炎病毒、人類免疫缺陷病毒和人類鉅細胞病毒；Aptima 細菌性陰道病和念珠菌性陰道炎試劑用於陰道炎的診斷；Aptima 新型冠狀病毒（SARS-CoV-2）和 Panther Fusion 新型冠狀病毒試劑用於檢測新型冠狀病毒；ThinPrep 系統用於細胞學應用；以及 Rapid Fetal Fibronectin Test 用於幫助醫生評估早產風險。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們比 Hologic 更喜歡的股票</li>
<li>投資高市盈率成長股</li>
<li>CAVA 股票上漲，盈利證實它是一家頂級成長股</li>
<li>股票情緒分析：工作原理</li>
<li>MarketBeat 周評 - 8/19 - 8/23</li>
<li>如何計算期權利潤</li>
<li>3 只高空頭頭寸股票準備進行利率削減擠壓</li>
</ul>
<p><strong>想看看其他對 HOLX 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Hologic, Inc.（納斯達克股票代碼：HOLX - 免費報告）的最新 13F 申報和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 你被欺騙了 615 天，而且還在繼續（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTEy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTEy"/></p>
<h2>現在是否值得投資 1,000 美元購買 Hologic 股票？</h2>
<p>在考慮 Hologic 之前，您會想聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票... 而 Hologic 不在名單上。</p>
<p>雖然 Hologic 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

豪洛捷

<p>Cypress Capital Group 在第二季度將其在 Hologic, Inc. (NASDAQ: HOLX) 的持股比例減少了 75.9%，出售了 9,607 股後，持有 3,050 股。該公司最新的申報顯示，其 Hologic 股票價值為$1,000。其他投資者也增持或建立了 Hologic 的持股，包括各種對沖基金。截至目前，公司股份的 94.73% 歸機構持有。Hologic 最近公佈了季度收益，並經歷了首席執行官 Stephen P. Macmillan 等內部人士的減持。分析師們為該股設定了各種價格目標</p>

<p>Cypress Capital Group lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 75.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,050 shares of the medical equipment provider's stock after selling 9,607 shares during the period. Cypress Capital Group's holdings in Hologic were worth $226,000 as of its most recent SEC filing.</p>
<ul>
<li>Time to buy these 3 healthcare companies that raised revenue guidance?</li>
</ul>
<div class="lb-trans"><p>Cypress Capital Group 在第二季度減持了 Hologic, Inc.（NASDAQ:HOLX - Free Report）的持股，根據該公司最近向證券交易委員會（SEC）提交的文件，持股比例下降了 75.9%。該公司在此期間賣出了 9,607 股，持有這家醫療設備提供商的 3,050 股股票。截至最近一次提交的 SEC 文件，Cypress Capital Group 持有的 Hologic 股份價值 226,000 美元。</p>
<ul>
<li>是時候購買這 3 家提高收入預測的醫療公司了嗎？</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently bought and sold shares of the business. iA Global Asset Management Inc. acquired a new position in Hologic in the 1st quarter valued at about $37,000. Mather Group LLC. purchased a new stake in Hologic in the 1st quarter valued at approximately $48,000. Massmutual Trust Co. FSB ADV raised its position in Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider's stock worth $54,000 after acquiring an additional 137 shares in the last quarter. Toth Financial Advisory Corp increased its holdings in shares of Hologic by 81.1% in the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider's stock valued at $60,000 after purchasing an additional 347 shares in the last quarter. Finally, Fidelis Capital Partners LLC purchased a new stake in Hologic during the first quarter worth about $63,000. 94.73% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也買入和賣出了該公司的股票。iA Global Asset Management Inc.在第一季度新建了 Hologic 的頭寸，價值約 37,000 美元。Mather Group LLC.在第一季度購入了一份價值約 48,000 美元的 Hologic 股票。Massmutual Trust Co. FSB ADV 在第一季度將其在 Hologic 的持倉增加了 24.7%。Massmutual Trust Co. FSB ADV 現在擁有 691 股這家醫療設備提供商的股票，價值 54,000 美元，比上一季度增加了 137 股。Toth Financial Advisory Corp 在第一季度將其在 Hologic 的持股增加了 81.1%。Toth Financial Advisory Corp 現在擁有 775 股這家醫療設備提供商的股票，價值 60,000 美元，比上一季度增加了 347 股。最後，Fidelis Capital Partners LLC 在第一季度購入了一份價值約 63,000 美元的 Hologic 股票。94.73% 的股份由對沖基金和其他機構投資者持有。</p>
</div><h2>Hologic Price Performance</h2>
<div class="lb-trans"><h2>Hologic 股價表現</h2>
</div><p>Shares of NASDAQ HOLX traded up $0.16 during mid-day trading on Friday, reaching $80.25. 1,106,135 shares of the company traded hands, compared to its average volume of 1,648,404. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $84.67. The firm has a market cap of $18.73 billion, a PE ratio of 40.94, a price-to-earnings-growth ratio of 2.64 and a beta of 0.99. The stock has a fifty day simple moving average of $77.75 and a 200-day simple moving average of $76.14. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.29.</p>
<ul>
<li>Can Butterfly Network Spread its Wings in 2023?</li>
</ul>
<div class="lb-trans"><p>NASDAQ HOLX 股票在週五的午間交易中上漲了 0.16 美元，達到 80.25 美元。公司股票交易量為 1,106,135 股，相比其平均交易量 1,648,404 股有所下降。Hologic, Inc.的 52 周最低價為 64.02 美元，52 周最高價為 84.67 美元。該公司的市值為 187.3 億美元，市盈率為 40.94，市盈增長比為 2.64，貝塔係數為 0.99。股票的 50 天簡單移動平均線為 77.75 美元，200 天簡單移動平均線為 76.14 美元。公司的資產負債比為 0.51，流動比率為 3.99，速動比率為 3.29。</p>
<ul>
<li>蝴蝶網絡能否在 2023 年擴展業務？</li>
</ul>
</div><p>Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm's quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.93 earnings per share. Equities research analysts anticipate that Hologic, Inc. will post 4.08 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Hologic（NASDAQ:HOLX - Get Free Report）於 7 月 29 日星期一公佈了其季度收益結果。這家醫療設備提供商報告稱，該季度每股收益為 1.06 美元，超過了 1.02 美元的共識預期 0.04 美元。該季度公司收入為 101 億美元，而分析師預計為 100 億美元。Hologic 的淨利潤率為 17.59%，淨資產回報率為 19.53%。公司季度收入同比增長了 2.7%。在去年同期的同一季度，該公司每股收益為 0.93 美元。股票研究分析師預計，Hologic, Inc.本財年的每股收益將達到 4.08 美元。</p>
</div><h2>Insider Activity at Hologic</h2>
<div class="lb-trans"><h2>Hologic 內部交易活動</h2>
</div><p>In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company's stock, valued at approximately $92,755,443.06. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the company's stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares of the company's stock, valued at approximately $92,755,443.06. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now owns 3,735 shares of the company's stock, valued at $310,415.85. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,280 shares of company stock valued at $1,469,973. Corporate insiders own 1.75% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Hologic 新聞中，首席執行官 Stephen P. Macmillan 於 7 月 17 日星期三交易中出售了 3,672 股 Hologic 股票。這些股票的平均價格為 80.13 美元，總交易額為 294,237.36 美元。交易完成後，首席執行官現在擁有公司股票 1,157,562 股，價值約 92,755,443.06 美元。該交易已在提交給證券交易委員會的文件中披露，可在此鏈接找到。另外，首席執行官 Stephen P. Macmillan 於 7 月 17 日星期三的交易中出售了公司股票 3,672 股。股票的平均價格為 80.13 美元，總價值為 294,237.36 美元。交易完成後，首席執行官現在直接持有公司股票 1,157,562 股，價值約 92,755,443.06 美元。該交易已在證券交易委員會的法律文件中披露，可通過 SEC 網站訪問。此外，內部人員 Brandon Schnittker 於 8 月 6 日星期二的交易中出售了 476 股 Hologic 股票。這些股票的平均價格為 83.11 美元，總價值為 39,560.36 美元。交易完成後，該內部人員現在持有公司股票 3,735 股，價值 310,415.85 美元。過去三個月，內部人員已出售了價值 1,469,973 美元的 18,280 股公司股票。公司內部人員持有公司股份的比例為 1.75%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of research firms have recently issued reports on HOLX. Royal Bank of Canada reiterated a &#34;sector perform&#34; rating and set a $82.00 price target on shares of Hologic in a research report on Friday, August 16th. Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $90.00 target price on shares of Hologic in a report on Tuesday, July 30th. StockNews.com downgraded shares of Hologic from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, August 10th. Stephens restated an &#34;overweight&#34; rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Finally, Argus upped their target price on Hologic from $89.00 to $95.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, May 9th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $87.60.</p>
<div class="lb-trans"><p>一些研究公司最近發佈了關於 HOLX 的報告。加拿大皇家銀行重申了對 Hologic 的 “行業表現” 評級，並設定了 82.00 美元的股價目標。Needham \u0026 Company LLC 重申了對 Hologic 的 “買入” 評級，並設定了 90.00 美元的目標股價。StockNews.com 將 Hologic 的股票評級從 “強買” 調降至 “買入”，並在 8 月 10 日的報告中指出。Stephens 重申了對 Hologic 的 “增持” 評級，並設定了 92.00 美元的股價目標。最後，Argus 將 Hologic 的目標股價從 89.00 美元上調至 95.00 美元，並給予該公司 “買入” 評級。四家研究分析公司對該股票給予持有評級，八家給予買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “中度買入”，平均目標股價為 87.60 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on HOLX</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 HOLX 的最新股票分析</strong></p>
</div><h2>Hologic Profile (Free Report)</h2>
<div class="lb-trans"><h2>Hologic 簡介（免費報告）</h2>
</div><p>Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.</p>
<div class="lb-trans"><p>Hologic, Inc（豪洛捷公司）開發、製造和供應診斷產品、醫學影像系統和婦女健康手術產品，通過早期檢測和治療服務於婦女健康。該公司通過四個部門運營：診斷、乳腺健康、婦科手術和骨骼健康。它提供 Aptima 分子診斷試劑以檢測感染微生物；Aptima 病毒載量試劑用於乙型肝炎病毒、丙型肝炎病毒、人類免疫缺陷病毒和人類鉅細胞病毒；Aptima 細菌性陰道病和念珠菌性陰道炎試劑用於陰道炎的診斷；Aptima 新型冠狀病毒（SARS-CoV-2）和 Panther Fusion 新型冠狀病毒試劑用於檢測新型冠狀病毒；ThinPrep 系統用於細胞學應用；以及 Rapid Fetal Fibronectin Test 用於幫助醫生評估早產風險。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Hologic</li>
<li>Investing in the High PE Growth Stocks</li>
<li>CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>MarketBeat Week in Review – 8/19 - 8/23</li>
<li>How to Calculate Options Profits</li>
<li>3 High Short-Interest Stocks Poised for a Rate Cut Squeeze</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>五隻我們比 Hologic 更喜歡的股票</li>
<li>投資高市盈率成長股</li>
<li>CAVA 股票上漲，盈利證實它是一家頂級成長股</li>
<li>股票情緒分析：工作原理</li>
<li>MarketBeat 周評 - 8/19 - 8/23</li>
<li>如何計算期權利潤</li>
<li>3 只高空頭頭寸股票準備進行利率削減擠壓</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HOLX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 HOLX 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Hologic, Inc.（納斯達克股票代碼：HOLX - 免費報告）的最新 13F 申報和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=HOLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ You’ve been lied to for 615 days, and counting (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 你被欺騙了 615 天，而且還在繼續（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTEy" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9112&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Hologic right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1,000 美元購買 Hologic 股票？</h2>
</div><p>Before you consider Hologic, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hologic 之前，您會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票... 而 Hologic 不在名單上。</p>
</div><p>While Hologic currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hologic 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

豪洛捷公司（NASDAQ:HOLX）的股票被 Cypress Capital Group 出售